SmartPA Criteria Proposal

Drug/Drug Class:	Antiemetic THC Derivative Agents PDL Edit
First Implementation Date:	April 4, 2019
Proposed Date:	December 17, 2020
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	☒Existing Criteria ☐Revision of Existing Criteria ☐New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: The Tetrahydrocannabinol (THC) derivative agents have indications that include prevention and treatment of nausea and vomiting associated with chemotherapy. Dronabinol and Marinol also have an indication for treating anorexia in patients with AIDS. The management of chemotherapy-induced nausea and vomiting is a critical aspect of treating cancer patients. The THC derivative agents are controlled substances and therefore need to be managed appropriately.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:

Preferred Agents	Non-Preferred Agents
• Dronabinol	• Cesamet® • Marinol®

Type of Criteria: ☐ **Increased risk of ADE** ☒ **Preferred Drug List**
☒ **Appropriate Indications** ☐ **Clinical Edit**

Data Sources: ☐ **Only Administrative Databases** ☒ **Databases + Prescriber-Supplied**

Setting & Population

- Drug class for review: Antiemetic THC Derivative Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with a trial on 1 or more preferred agents
  - Documented trial period for preferred agents (2 claims in 90 days) **OR**
  - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:	☐	Progress Notes:	☐
MedWatch Form:	☐	Other:	☐

Disposition of Edit

Denial: Exception "0160" (Preferred Drug List Edit)
Rule Type: PDL

Default Approval Period

1 year

References

1. Drug Effectiveness Review Project – Drug Class Review on Antiemetics - Newer. Center for Evidence-Based Policy, Oregon Health & Science University; January 2009; Expanded Scan August 2018.
2. Evidence-Based Medicine and Fiscal Analysis: "Antiemetic Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; November 2020.
1. Evidence-Based Medicine Analysis: "Antiemetics - 5-HT3, THC Derivatives, NK1 & Other Agents", UMKC-DIC; September 2020.
2. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2019.
3. USPDI, Micromedex; 2020.
4. Drug Facts and Comparisons On-line; 2020.